<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>http://hboevidence.wikis.unsw.edu.au/index.php?action=history&amp;feed=atom&amp;title=Granpeesheh</id>
	<title>Granpeesheh - Revision history</title>
	<link rel="self" type="application/atom+xml" href="http://hboevidence.wikis.unsw.edu.au/index.php?action=history&amp;feed=atom&amp;title=Granpeesheh"/>
	<link rel="alternate" type="text/html" href="http://hboevidence.wikis.unsw.edu.au/index.php?title=Granpeesheh&amp;action=history"/>
	<updated>2026-10-04T14:39:49Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.31.0</generator>
	<entry>
		<id>http://hboevidence.wikis.unsw.edu.au/index.php?title=Granpeesheh&amp;diff=99&amp;oldid=prev</id>
		<title>Gordoben: Imported from Wikispaces</title>
		<link rel="alternate" type="text/html" href="http://hboevidence.wikis.unsw.edu.au/index.php?title=Granpeesheh&amp;diff=99&amp;oldid=prev"/>
		<updated>2018-07-05T02:44:43Z</updated>

		<summary type="html">&lt;p&gt;Imported from Wikispaces&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;==&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 140%;&amp;quot;&amp;gt;Oxygen enriched air at 1.3 atmospheres did not improve function in children with autism spectrum disorder.&amp;lt;/span&amp;gt;== &lt;br /&gt;
{| &lt;br /&gt;
| '''&amp;lt;span style'''&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 130%;&amp;quot;&amp;gt;1. No evidence of improved function following 1.3 atm hyperbaric oxygen at 24-28% O2 &amp;lt;/span&amp;gt;'''&amp;lt;br&amp;gt;**&amp;lt;span style'''&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 130%;&amp;quot;&amp;gt;compared to placebo.&amp;lt;/span&amp;gt;''' &lt;br /&gt;
|-&lt;br /&gt;
|}&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Citation/s:''' Granpeesheh D, Tarbox J, Dixon D, Wilke A, Allen M, Bradstreet J. Randomized trial of hyperbaric oxygen therapy for children. Research in Autism Spectrum Disorders 2010;4:268-275.&amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Lead author's name and email:''' Doreen Granpeesheh d.dixon@centreforautism.com&amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Three-part Clinical Question:''' In children with autistic spectrum disorder, does the administration of hyperbaric oxygen therapy compared to standard therapy lead to a measureable improvement in communication and social interaction?&amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Search Terms:''' autistic disorder, autism spectrum disorder&amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''The Study:''' Double-blinded concealed randomised controlled trial with intention-to-treat.&amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''The Study Patients:''' English speaking children aged 2-14yrs with diagnosed autism spectrum disorder according to DSM-IV criteria.&amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Control group''' (N = 23; 16 analysed): 80 x 1 hour sessions over 15 weeks breathing air at ambient pressure in the chamber &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Experimental group''' (N = 23; 18 analysed): as above but breathing 24-28% oxygen at 1.3 ATA.&amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
**&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;The Evidence:&amp;lt;/span&amp;gt;'''&lt;br /&gt;
{| &lt;br /&gt;
| &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;'''&amp;lt;span style'''&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;Outcome&amp;lt;/span&amp;gt;'''&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;'''&amp;lt;span style'''&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;Time to Outcome&amp;lt;/span&amp;gt;'''&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;'''&amp;lt;span style'''&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;Control group&amp;lt;/span&amp;gt;'''&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;'''&amp;lt;span style'''&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;Experimental group&amp;lt;/span&amp;gt;'''&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;'''&amp;lt;span style'''&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;Relative risk increase&amp;lt;/span&amp;gt;'''&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;'''&amp;lt;span style'''&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;Absolute risk increase&amp;lt;/span&amp;gt;'''&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;'''&amp;lt;span style'''&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;NNT&amp;lt;/span&amp;gt;'''&amp;lt;/span&amp;gt; &lt;br /&gt;
|-&lt;br /&gt;
| &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;'''&amp;lt;span style'''&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;improved ADOS &amp;lt;/span&amp;gt;'''(see comments)&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;15 weeks&amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;0.174&amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;0.217&amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;25%&amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;0.043&amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;23&amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; &lt;br /&gt;
|-&lt;br /&gt;
|^   |||||| &amp;lt;span style'''&amp;quot;display: block; text-align: right;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;95% CIs:&amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;156% to -100%&amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;0.18 to -0.27&amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;NNT ''' 5 to INF; NNH ''' 4 to INF&amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; &lt;br /&gt;
|-&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
{| &lt;br /&gt;
| &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;'''&amp;lt;span style'''&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;Non-Event Outcomes&amp;lt;/span&amp;gt;'''&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;'''&amp;lt;span style'''&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;Time to outcome/s&amp;lt;/span&amp;gt;'''&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;'''&amp;lt;span style'''&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;Control group &amp;lt;/span&amp;gt;'''&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;'''&amp;lt;span style'''&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;Experimental group&amp;lt;/span&amp;gt;'''&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;'''&amp;lt;span style'''&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;P-value&amp;lt;/span&amp;gt;'''&amp;lt;/span&amp;gt; &lt;br /&gt;
|-&lt;br /&gt;
| '''&amp;lt;span style'''&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;secondary outcome measure VABS-II communication change&amp;lt;/span&amp;gt;''' || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;80 sessions&amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;16&amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;18&amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;0.51&amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; &lt;br /&gt;
|-&lt;br /&gt;
| '''&amp;lt;span style'''&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;VABS-II daily living skills change&amp;lt;/span&amp;gt;''' || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;80 sessions&amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;16&amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;18&amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;0.75&amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; &lt;br /&gt;
|-&lt;br /&gt;
|}&lt;br /&gt;
**&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;Comments:&amp;lt;/span&amp;gt;'''&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;1. Randomisation was by coin toss after matching pairs for age and hours of applied behavioural analysis received. Matching and random assignment done by investigator who was otherwise blinded. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;2. The study power too low to detect clinically important differences between groups.&amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;3. ADOS is 'The Autism Diagnostic Observation Schedule'. This is a semi-structured assessment of communication, social interaction, and play The ADOS consists of four modules, each of which is appropriate for children and adults of differing developmental and language levels, ranging from nonverbal to verbally-fluent.&amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;4. VABS-II is the 'Vineland Adaptive Bahaviour Scale' and a measure of personal and social skills required for everyday living. &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Appraised by:''' Andre Venning, Prince of Wales Hyperbaric dept. Randwick NSW; Tuesday, 21 August 2012&amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Email:''' akvenn@gmail.com&amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Kill or Update By:''' June 2020&amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:sumhorsa.gif|center]]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;display: block; font-size: 200%; text-align: center;&amp;quot;&amp;gt;[[Neuro - miscellaneous  |  BACK]]&amp;lt;/span&amp;gt;&lt;/div&gt;</summary>
		<author><name>Gordoben</name></author>
		
	</entry>
</feed>